接受生物制剂治疗且生活质量受损的炎症性肠病患者可从IBD专科护士支持中获益:德国IBDBIO-ASSIST随机对照试验结果
IBDBIO-ASSIST随机对照试验将1086例接受生物制剂治疗的炎症性肠病患者随机分为常规护理对照组和增加IBD专科护士支持的干预组,主要终点为6、12、18个月时的疾病特异性生活质量(sIBDQ)。总体意向治疗分析未显示组间显著差异,但基线生活质量受损(EQ-VAS<75)患者中,干预组sIBDQ在12个月时改善达显著并持续至18个月(基线IG 4.24 vs CG 4.31;18个月IG 5.02 vs CG 4.76;p=0.017)。
要点
- 总体意向治疗分析中两组sIBDQ在评估时间点无显著差异。
- 基线生活质量受损(EQ-VAS<75)患者中,IBD专科护士额外护理使sIBDQ在12个月时显著改善并持续至18个月。
- 基线治疗高满意度及较高sIBDQ值可能解释总体样本无显著差异。
核心结论
- 基线治疗高满意度和较高基线sIBDQ值可能导致总体样本sIBDQ评分无显著差异;但生活质量受损患者从IBD专科护士额外护理中获得显著获益,长期sIBDQ有意义的改善。
研究设计与样本
- 随机对照试验(IBDBIO-ASSIST),在德国纳入1086例接受生物制剂治疗的炎症性肠病患者,随机分为常规护理对照组(CG)或常规护理加IBD专科护士支持的干预组(IG),主要终点为6、12、18个月时的疾病特异性生活质量(sIBDQ)。
主要发现
- 基线时两组患者对治疗高度满意,sIBDQ值相对较高(范围1-7;CG 5.12;IG 4.92)。
- 意向治疗(ITT)分析总体样本中,两组sIBDQ在评估时间点无显著差异。
- 符合方案分析中,基线生活质量受损(EQ-VAS<75[中位数])患者sIBDQ在6个月内改善,12个月时达显著并持续至18个月(基线:IG 4.24;CG 4.31;18个月:IG 5.02;CG 4.76;p=0.017)。
关键数值与推荐
- 主要终点为疾病特异性生活质量(sIBDQ),在6、12和18个月评估。
- 基线生活质量受损定义为EQ-VAS<75(中位数)。
- 基线sIBDQ范围1-7;CG 5.12;IG 4.92。
- 基线生活质量受损患者18个月时sIBDQ:IG 5.02 vs CG 4.76(p=0.017)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 基线时患者对治疗高度满意且sIBDQ值相对较高,可能导致总体样本sIBDQ评分无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IBDBIO-ASSIST was a randomised controlled trial assessing the efficacy of care provided by IBD nurse specialists in Germany in improving health-related quality of life (QoL) in IBD patients on biologic therapy. AIM: To evaluate patient-related outcomes and economic consequences associated with integrating IBD nurses into usual care. METHODS: We randomly assigned 1086 patients with IBD on biologic therapy to a control group (CG) receiving usual care or an intervention group (IG) receiving additional care from an IBD nurse specialist. The primary outcome was disease-specific QoL (sIBDQ) assessed at 6, 12 and 18 months. RESULTS: At baseline, patients in both groups were highly satisfied with their treatment situation and had relatively high sIBDQ values (range: 1-7; CG: 5.12; IG: 4.92). In the intention-to-treat (ITT) analysis of the overall sample, there was no significant difference in sIBDQ between groups at the assessment time points. However, a per-protocol analysis of patients with impaired QoL at baseline (EQ-VAS < 75 [median]), showed improvement in sIBDQ over 6 months that became significant at month 12 and remained significant through month 18 (baseline: IG 4.24; CG 4.31; 18 months: IG 5.02; CG 4.76; p = 0.017). CONCLUSION: High baseline satisfaction of IBD patients with treatment and the relatively high baseline sIBDQ values may have contributed to the lack of significant difference in sIBDQ scores for the overall sample. However, patients with impaired QoL derived significant benefit from additional care provided by an IBD nurse specialist, leading to meaningful improvements in sIBDQ over the long term.
引用
- Bokemeyer B, Plachta-Danielzik S, Steiner IM, et al. Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study). Aliment Pharmacol Ther. 2024. PMID: 38429885. doi:10.1111/apt.17926
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。